New Software and Instrumentation Introduced at ASMS Enhance
Performance while Increasing Laboratory Productivity
VANCOUVER, British Columbia--(BUSINESS WIRE)--May. 21, 2012--
ASMS 2012 –- Thermo Fisher Scientific Inc. (NYSE:TMO), the world
leader in serving science, today launched innovative software and
instrumentation that extend the capabilities of its flagship mass
spectrometry portfolio. The new Thermo Scientific technologies made
their debut at the ASMS Conference on Mass Spectrometry and Allied
Topics, being held in Vancouver from May 20 - 24.
The analytical power of the company’s highly successful LTQ
Orbitrap® hybrid platform is now enhanced by a new suite
of software designed to further advance the performance of its recently
introduced Elite™
and Q
Exactive™ mass spectrometers. Next-generation SIEVE™
2.0 software increases throughput during complex metabolite and
protein biomarker discovery experiments, while new ExactFinder™
2.0 software dramatically improves analysis time in the rapidly
changing field of food safety testing. Thermo Fisher also introduced Protein
Deconvolution software to fully leverage the
high-resolution/accurate mass (HR/AM) data produced by the Q Exactive
system during complex protein analysis. These three new offerings are
among eight software packages being introduced at ASMS.
For laboratory customers who need to perform quantitative and
qualitative analysis, but currently have limited capital budgets, Thermo
Fisher launched the new Exactive™
Plus liquid chromatography/mass spectrometry (LC/MS) system. The
Exactive Plus system is designed specifically to address the need for
high-throughput screening of compounds in a range of applications,
including drug metabolism/pharmacokinetics (DMPK), metabolomics,
forensic toxicology, environmental analysis and food safety testing. The
new Exactive Plus LC/MS can be readily upgraded to match the higher
performance of the premier Q Exactive mass spectrometer.
“Our leading mass spectrometry technologies are consistently enabling
our customers’ important discoveries in medical research, and meeting
their growing needs for environmental and consumer safety testing,” said
Marc N. Casper, president and chief executive officer of Thermo Fisher.
“Like our customers, we never stop innovating, and these new software
launches take our incredibly successful Orbitrap platform to the next
level, particularly our Elite and Q Exactive systems. In today’s
economic environment, many laboratories are under funding pressure, yet
need to deliver results. Our new Exactive Plus gives these customers
another option that solves their analytical challenges today, and can be
upgraded to full Q Exactive performance in the future.”
Thermo Fisher’s commitment to advancing triple quadrupole technology is
evident in its new TSQ
8000™ high-performance gas chromatography-mass spectrometry system
(GC-MS/MS), also launched at ASMS. The TSQ 8000 system allows users to
view targeted compounds at lower concentrations, making even more
complex analyses possible. Compatible with the company’s leading TraceFinder™
2.1 software, the TSQ 8000 GC-MS/MS is designed for routine
applications, including the identification of food and environmental
contaminants.
To see the entire Thermo Fisher portfolio of new mass spectrometry
instruments, consumables and software, visit the Thermo Scientific
hospitality suite in the Parkview Terrace at the Vancouver Convention
Center or online at www.thermofisher.com/news.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science. Our mission is to enable our customers to make the world
healthier, cleaner and safer. With revenues of $12 billion, we have
approximately 39,000 employees and serve customers within pharmaceutical
and biotech companies, hospitals and clinical diagnostic labs,
universities, research institutions and government agencies, as well as
in environmental and process control industries. We create value for our
key stakeholders through three premier brands, Thermo Scientific, Fisher
Scientific and Unity™ Lab Services, which offer a unique combination of
innovative technologies, convenient purchasing options and a single
solution for laboratory operations management. Our products and services
help our customers solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward-looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements are set forth in the company’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2012, under the caption “Risk Factors,”
which is on file with the Securities and Exchange Commission and
available in the “Investors” section of our website under the heading
“SEC Filings.” Important factors that could cause actual results to
differ materially from those indicated by forward-looking statements
include risks and uncertainties relating to: the need to develop new
products and adapt to significant technological change; implementation
of strategies for improving growth; general worldwide economic
conditions and related uncertainties; dependence on customers' capital
spending policies and government funding policies; the effect of
exchange rate fluctuations on international operations; the effect of
healthcare reform legislation; use and protection of intellectual
property; the effect of changes in governmental regulations; and the
effect of laws and regulations governing government contracts, as well
as the possibility that expected benefits related to the acquisitions of
Dionex and Phadia may not materialize as expected. While we may elect to
update forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so, even if estimates change
and, therefore, you should not rely on these forward-looking statements
as representing our views as of any date subsequent to today.
Source: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific, Inc.
Media Contact Information:
Ron
O’Brien, 781-622-1242
ron.obrien@thermofisher.com
or
Investor
Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
